Comparative Pharmacology
Head-to-head clinical analysis: ISTURISA versus JUBEREQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISTURISA versus JUBEREQ.
ISTURISA vs JUBEREQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISTURISA (osilodrostat) is an orally administered inhibitor of 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol synthesis in the adrenal cortex. By blocking this enzyme, it reduces cortisol production. It also inhibits aldosterone synthase (CYP11B2) to a lesser extent.
Selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER), causing its degradation and thereby inhibiting ER-mediated signaling and tumor growth.
1 mg orally twice daily, titrated based on cortisol levels and tolerability; maximum dose 7 mg twice daily.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life of approximately 5–7 hours; clinical context: supports twice-daily dosing for steady-state attainment.
12-15 hours (terminal elimination half-life); prolonged in renal impairment (up to 40 hours in GFR <30 mL/min).
Primarily hepatic metabolism via CYP3A4; elimination is mainly fecal (approximately 80%) and renal (about 10% as unchanged drug).
Primarily renal (70-80% as unchanged drug); 10-15% via biliary/fecal; 5-10% metabolized to inactive glucuronide conjugates.
Category C
Category C
Cortisol Synthesis Inhibitor
Cortisol Synthesis Inhibitor